Shell Asset Management Co. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 12.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,038 shares of the biopharmaceutical company’s stock after selling 1,188 shares during the period. Shell Asset Management Co.’s holdings in Halozyme Therapeutics were worth $321,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HALO. Covestor Ltd acquired a new stake in Halozyme Therapeutics during the 4th quarter worth about $114,000. Acadian Asset Management LLC acquired a new stake in Halozyme Therapeutics during the 4th quarter worth about $122,000. Lazard Asset Management LLC grew its position in Halozyme Therapeutics by 25.2% during the 4th quarter. Lazard Asset Management LLC now owns 3,177 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 639 shares during the period. Scissortail Wealth Management LLC acquired a new stake in Halozyme Therapeutics during the 4th quarter worth about $131,000. Finally, KBC Group NV acquired a new stake in Halozyme Therapeutics during the 4th quarter worth about $175,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.
Halozyme Therapeutics Trading Down 0.6 %
HALO stock opened at $45.13 on Friday. The company has a current ratio of 8.85, a quick ratio of 8.42 and a debt-to-equity ratio of 3.03. Halozyme Therapeutics, Inc. has a 12-month low of $31.36 and a 12-month high of $52.98. The stock has a market cap of $6.23 billion, a price-to-earnings ratio of 15.09, a PEG ratio of 0.74 and a beta of 1.20. The business’s 50-day moving average is $47.00 and its 200 day moving average is $41.32.
Analyst Upgrades and Downgrades
HALO has been the topic of several analyst reports. SVB Leerink began coverage on Halozyme Therapeutics in a research report on Monday, May 23rd. They set an “outperform” rating and a $52.00 price target on the stock. StockNews.com cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Finally, The Goldman Sachs Group raised their target price on Halozyme Therapeutics from $48.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, May 26th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $52.33.
Halozyme Therapeutics Profile
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
- Get a free copy of the StockNews.com research report on Halozyme Therapeutics (HALO)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.